Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.52 |
| ▸ | FPR2 | P25090 | 1/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | ADCY6 | O43306 | 1/20 | 0.45 |
| ▸ | ADCY3 | O60266 | 1/20 | 0.45 |
| ▸ | ADCY9 | O60503 | 1/20 | 0.45 |
| ▸ | ADCY5 | O95622 | 1/20 | 0.45 |
| ▸ | ADCY8 | P40145 | 1/20 | 0.45 |
| ▸ | GCGR | P47871 | 1/20 | 0.45 |
| ▸ | ADCY7 | P51828 | 1/20 | 0.45 |
| ▸ | ADCY2 | Q08462 | 1/20 | 0.45 |
| ▸ | ADCY1 | Q08828 | 1/20 | 0.45 |
| ▸ | ADCY4 | Q8NFM4 | 1/20 | 0.45 |
| ▸ | FAAH | O00519 | 1/20 | 0.44 |
| ▸ | P2RY1 | P47900 | 3/20 | 0.44 |
| ▸ | IDH1 | O75874 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4096999 | 0.85 | TRPV1 (0.63) | TRPV1FPR2EPHX2ALDH1A1HPGD | |
| SCHEMBL4092078 | 0.81 | TRPV1 (0.63) | TRPV1FPR2EPHX2ALDH1A1HPGD | |
| SCHEMBL4097353 | 0.76 | GCGR (0.72) | TRPV1EPHX2ADCY6ADCY3ADCY9 | |
| SCHEMBL6289141 | 0.76 | GCGR (0.65) | TRPV1FPR2EPHX2ALDH1A1HPGD | |
| SCHEMBL2643012 | 0.75 | GCGR (0.49) | TRPV1FPR2EPHX2ALDH1A1HPGD | |
| SCHEMBL2657722 | 0.74 | GCGR (0.61) | TRPV1EPHX2ALDH1A1HPGDADCY6 | |
| SCHEMBL4091185 | 0.72 | GCGR (0.58) | TRPV1ADCY6ADCY3ADCY9ADCY5 | |
| SCHEMBL6289580 | 0.72 | EPHX2 (0.64) | TRPV1FPR2EPHX2HPGDNR1H4 | |
| SCHEMBL2875822 | 0.72 | P2RY1 (0.60) | TRPV1EPHX2P2RY1CA12CA1 | |
| SCHEMBL2646738 | 0.72 | GCGR (0.54) | TRPV1EPHX2ALDH1A1HPGDADCY6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6953812-B2 | Glucagon antagonists/inverse agonists | NOVO NORDISK, INC. (DK) | 2005-10-11 | — | — | US | disclosed |
| US-20040024045-A1 | Glucagon antagonists/inverse agonists | PFIZER INC | 2004-02-05 | — | — | US | disclosed |
| US-6562807-B2 | For prophylaxis and therapy of hyperglycemia, Type 1 diabetes, Type 2 diabetes, disorders of the lipid metabolism, such as dyslipidemia, and obesity | NOVO NORDISK A/S (DK) | 2003-05-13 | — | — | US | disclosed |
| EP-1296942-A1 | GLUCAGON ANTAGONISTS/INVERSE AGONISTS | Novo Nordisk A/S (DK) | 2003-04-02 | — | — | EP | disclosed |
| US-20020143186-A1 | Glucagon antagonists/inverse agonists | PFIZER INC | 2002-10-03 | — | — | US | disclosed |
| WO-2002000612-A1 | GLUCAGON ANTAGONISTS/INVERSE AGONISTS | NOVO NORDISK A/S (DK) | 2002-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040024045-A1 | Glucagon antagonists/inverse agonists | GLP1R, GPR119, GCGR | TRPV1 2269/4885FPR2 1421/4885EPHX2 3116/4885 |
| US-20020143186-A1 | Glucagon antagonists/inverse agonists | GLP1R, GPR119, GCGR | TRPV1 2269/4885FPR2 1421/4885EPHX2 3116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.